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Home mechanical ventilation. A growing challenge in
an aging society
Simplified ventilator technology and spin off effects from
the diagnostic advances of sleep medicine are two key
factors behind the increasing application of home mechan-
ical ventilation (HMV). There are consensual reports from
many countries1–4 that HMV treatment prevalence is
increasing, and a steady-state seems not to has been
reached. One part of the explanation is that HMV prescrip-
tion is still cumulative, i.e. new patients are started on
HMV at considerably higher rate than they die off. Another
factor affecting the treatment prevalence is the increasing
number of elderly, due to the progressive increase in life
expectancy in the western countries. Moreover, today’s
elderly have a substantial potential for long, disability-free,
active and fulfilling lives.5 One might assume that diminish-
ing numbers of patients with ‘‘old diseases’’, such as post-
polio, unfused scoliosis or tuberculosis sequelae, would
dampen the increasing need for HMV services, but this
seems not yet to be the case. Furthermore, the Pickwickian
patients constitute a rapidly growing (in a double sense)
problem.2
This issue of Respiratory Medicine presents two reports
with data that should be of interest for those who provide
respiratory home care. Farrero et al.6 focus on the elderly
(75+) patients, who comprise 8% of the total number of
patients on HMVat their clinic in Barcelona. This figure is not
unreasonable, the Swedish Ventilator and Oxygen Register
(Swedevox) reports that 12% of adult Swedish HMV patients
are older than 75 years.7 Farrero et al. found a significantly
higher rate of early uncompliant patients among the elderly
(11% vs. 4% for patients below 75). The corresponding figures
from Sweden (Swedevox, unpublished data) are 6.0% vs.
3.5%, a difference that is not significant (although early
failures may be underreported). Finally, Farrero et al. found
good long-term results for compliant elderly patients
(improvement in blood gases as well as for hospitalisation
rates).
The results of Farrero et al. are supported by those of
Laub and Midgren7 who in a nationwide prospective study
found significant but nevertheless relatively small effects of
age on survival in the HMV population (Fig. 1). A five-year
survival of almost 50% for HMV patients aged 75 or more6,7 isont matter & 2006 Elsevier Ltd. All rights reserved.
2006.10.006not a bad figure compared to many other treatments for life-
threatening disorders. Both Farrero and Laub report (not
unexpectedly) that patients with amyotrophic lateral
sclerosis (ALS) have by far the worst survival, with a
eightfold risk for death in ALS vs. nonALS in the Laub study.
The data presented by Laub indicate that other diagnosis-
related differences in survival are of limited magnitude,
with a relative risk of two between worst (lung and tbc) and
best (scoliosis, Pickwick). The results contrast to survival
data from smaller retrospective studies,8 which points to
the problems of case mix and patient selection in single
centre studies. The conclusion that can be drawn from the
studies of Farrero and Laub is that neither age nor diagnosis
per se (except ALS) should be important factors in the HMV
decision-making. Age alone is a poor marker of potential
clinical benefit of HMV therapy.
A thought-provoking finding in the Laub study is that
concomitant oxygen was associated with a worse prognosis.
This may of course reflect a larger component of lung
parenchymal disease. From my personal experience, how-
ever, concomitant oxygen is only occasionally required, once
the ventilator settings have been adequately adjusted. This
point of view is at least partially supported by the
observation that bigger centres (with presumed larger
experience) used concomitant oxygen only half as often as
did smaller centres.
The Laub study tries to address a question that seldom has
been studied in previous investigations, namely if survival is
dependant on caregiver-related factors. Earlier data from
the Swedevox register show that there are considerable
differences in the provision of HMV, with respect to centre
size (and presumed experience) and geographical preva-
lence (availability? utilization?) of HMV.2 According to Laub’s
data,7 these quantitative differences do not affect survival.
The somewhat surprising finding that centres with more
experience do not report longer patient survival could
perhaps be due to differences in case mix. With greater
experience, these centres may be more willing to care for
the difficult cases, with complex risk factors that may not be
reflected by simple register data, such as diagnosis, lung
function data, blood gases and age.
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Figure 1 Kaplan–Meyer plot of survival in 1526 patients (580
deceased) on home mechanical ventilation, prospectively
followed in the Swedish Ventilator and Oxygen register
(Swedevox), based on Laub and Midgren7 and previously
unpublished data.
Editorial 1067In conclusion, these two reports indicate that HMV should
be provided according to clinical needs, i.e. symptomatic
hypoventilation, regardless of age, underlying diagnosis
(with ALS as a case for discussion) or hospital size. Due to
considerable differences in case mix and clinical practise
between different HMV centres, future studies on prognostic
factors must be multicentric or based on national registers.References
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